Related Experiment Video

Updated: May 29, 2026

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

The biology and therapeutic implications of HDACs in the heart

Timothy A McKinsey1

  • 1Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, CO 80045-0508, USA. timothy.mckinsey@ucdenver.edu

Handbook of Experimental Pharmacology
|September 1, 2011
PubMed

Insights

Histone deacetylases (HDACs) regulate pathological cardiac remodeling. HDAC inhibitors show promise in animal models, suggesting potential for new heart failure therapies.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Pharmacology

Background:

  • The heart undergoes pathological remodeling in response to stress, leading to heart failure.
  • Histone deacetylases (HDACs) are increasingly recognized as key regulators of this remodeling process.
  • Existing research indicates HDAC inhibitors can mitigate adverse cardiac remodeling in preclinical models.

Purpose of the Study:

  • To review the specific roles of individual HDAC isoforms in cardiac remodeling.
  • To discuss the therapeutic potential of HDAC inhibitors for cardiovascular diseases.
  • To identify challenges in developing HDAC-directed therapies for heart conditions.

Main Methods:

  • Review of current literature on HDACs in cardiac remodeling.
  • Analysis of preclinical data on HDAC inhibitors in heart failure models.
  • Discussion of the functional roles of different HDAC isoforms in the heart.

Main Results:

  • HDACs act as both positive and negative regulators in pathological cardiac remodeling.
  • Small molecule HDAC inhibitors have shown efficacy in animal models of heart failure.
  • Understanding individual HDAC isoform functions is crucial for targeted therapy.

Conclusions:

  • HDACs are critical targets for managing cardiac remodeling and heart failure.
  • Further research is needed to overcome challenges in developing HDAC-based cardiovascular therapies.
  • Targeting specific HDAC isoforms may offer a novel therapeutic strategy for cardiovascular indications.

More Related Videos

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes05:06

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes

Published on: May 5, 2020

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...